Dr John Joseph Nelson, MD | |
150 Reynoir St, Biloxi, MS 39530-4130 | |
(228) 432-1571 | |
Not Available |
Full Name | Dr John Joseph Nelson |
---|---|
Gender | Male |
Speciality | Pathology |
Experience | 18 Years |
Location | 150 Reynoir St, Biloxi, Mississippi |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1912080235 | NPI | - | NPPES |
Facility Name | Location | Facility Type |
---|---|---|
Merit Health Biloxi | Biloxi, MS | Hospital |
Memorial Hospital At Gulfport | Gulfport, MS | Hospital |
Garden Park Medical Center | Gulfport, MS | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Professional Pathology Associates | 0446311492 | 3 |
News Archive
Aromatase inhibitors (AIs)—drugs that stop the production of estrogen in women—are standard adjuvant therapy for post-menopausal women with hormone-receptor positive breast cancer.
Medical researchers at the University of Alberta have discovered the structure of a potential drug target for a rare genetic disease, paving the way for an alternative treatment for the condition.
Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has been awarded a contract for $2.5 million from the U.S. Department of Defense (DOD) to support the continuing development of monoclonal antibody (mAb) therapies against staphylococcal-derived toxins and pathogenic staphylococcal strains.
Ampio Pharmaceuticals, Inc., a clinical stage developer of new uses for previously approved drugs and new molecular entities, announces that its common stock has been approved for listing on the NASDAQ Capital Market.
With an ever-increasing volume of electronic data being collected by the healthcare system, researchers are exploring the use of machine learning—a subfield of artificial intelligence—to improve medical care and patient outcomes.
› Verified 1 days ago
Entity Name | Professional Pathology Associates |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1174516108 PECOS PAC ID: 0446311492 Enrollment ID: O20081209000337 |
News Archive
Aromatase inhibitors (AIs)—drugs that stop the production of estrogen in women—are standard adjuvant therapy for post-menopausal women with hormone-receptor positive breast cancer.
Medical researchers at the University of Alberta have discovered the structure of a potential drug target for a rare genetic disease, paving the way for an alternative treatment for the condition.
Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has been awarded a contract for $2.5 million from the U.S. Department of Defense (DOD) to support the continuing development of monoclonal antibody (mAb) therapies against staphylococcal-derived toxins and pathogenic staphylococcal strains.
Ampio Pharmaceuticals, Inc., a clinical stage developer of new uses for previously approved drugs and new molecular entities, announces that its common stock has been approved for listing on the NASDAQ Capital Market.
With an ever-increasing volume of electronic data being collected by the healthcare system, researchers are exploring the use of machine learning—a subfield of artificial intelligence—to improve medical care and patient outcomes.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Dr John Joseph Nelson, MD Po Box 1936, Biloxi, MS 39533-1936 Ph: (228) 436-9957 | Dr John Joseph Nelson, MD 150 Reynoir St, Biloxi, MS 39530-4130 Ph: (228) 432-1571 |
News Archive
Aromatase inhibitors (AIs)—drugs that stop the production of estrogen in women—are standard adjuvant therapy for post-menopausal women with hormone-receptor positive breast cancer.
Medical researchers at the University of Alberta have discovered the structure of a potential drug target for a rare genetic disease, paving the way for an alternative treatment for the condition.
Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has been awarded a contract for $2.5 million from the U.S. Department of Defense (DOD) to support the continuing development of monoclonal antibody (mAb) therapies against staphylococcal-derived toxins and pathogenic staphylococcal strains.
Ampio Pharmaceuticals, Inc., a clinical stage developer of new uses for previously approved drugs and new molecular entities, announces that its common stock has been approved for listing on the NASDAQ Capital Market.
With an ever-increasing volume of electronic data being collected by the healthcare system, researchers are exploring the use of machine learning—a subfield of artificial intelligence—to improve medical care and patient outcomes.
› Verified 1 days ago
Dr. Amanda Lynn Kitson, MD Pathology Medicare: Medicare Enrolled Practice Location: 301 Fisher St, Biloxi, MS 39534 Phone: 122-837-6255 | |
Dr. Brad Elliot Wheeler, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 300 Fisher Street, Biloxi, MS 39534 Phone: 228-376-4472 Fax: 228-376-0148 | |
Edward Shumski, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 150 Reynoir St, Biloxi, MS 39530 Phone: 228-432-1571 | |
Dr. Marjorie Grace Teng Sy, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 400 Veterans Ave, Pathology And Laboratory Medicine Service, Biloxi, MS 39531 Phone: 856-438-5581 | |
Dr. Brian David Arbogast, MD Pathology Medicare: Medicare Enrolled Practice Location: 150 Reynoir St, Biloxi, MS 39530 Phone: 228-432-1571 Fax: 228-436-1340 | |
Eldon Mcclain, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 150 Reynoir St, Biloxi, MS 39530 Phone: 228-432-1571 |